Bessemer Group’s Adicet Bio ACET Stock Holding History

Bessemer Group’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-13	Closed	-$12K	–	1753
2018 Q4	$12K	Hold	13	–	–	﹤0.01%	1614
2018 Q3	$21K	Sell	13 -1	-7%	-$1.3K	﹤0.01%	1442
2018 Q2	$14K	Buy	+14	New	+$15.1K	﹤0.01%	1464

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bessemer Group's ACET Position: Q1 2019 in Review

Bessemer Group sold out of Adicet Bio (ACET) in Q1 2019, closing a stake of 13 shares — an estimated $12K sold.

Bessemer Group first reported a position in ACET in Q2 2018 and held it in 3 quarters. The position peaked at $21K in Q3 2018. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2019.

Bessemer Group reported no remaining Adicet Bio position as of Q1 2019 after selling out during the quarter.
Bessemer Group sold 13 Adicet Bio shares in Q1 2019, an estimated $12K.
Bessemer Group first reported a position in Adicet Bio in Q2 2018 and held it in 3 quarters.
Bessemer Group's Adicet Bio position peaked at $21K in Q3 2018.
49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2019.

Based on Bessemer Group's 13F filing for Q1 2019, filed 13 May 2019.